For patients with transthyretin amyloidosis (ATTR amyloidosis), administration of an RNA interference therapeutic agent, patisiran, over 12 months results in preserved functional capacity, according ...
Researchers at Boston Medical Center (BMC) and Boston University (BU) Chobanian & Avedisian School of Medicine, in collaboration with an international team of scientists, shared findings from a new ...
Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating transthyretin (ATTR) amyloidosis at a recent medical conference in Chicago.
Early detection and treatment of hereditary transthyretin-related amyloidosis via genetic counseling are crucial. Yet, not all at-risk individuals seek genetic counseling, and management for ...
In their study published in the Mayo Clinic Proceedings, UAB researchers collaborated with researchers from Weill Cornell Medicine and Columbia University to show that carpal tunnel syndrome preceded ...
Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine led a nationwide study to examine the role of carpal tunnel syndrome in predicting the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results